This peptide is one of the few peptides where nasal administration competes effectively with injection
Human responses are variable, and the outcomes may depend on the overall health of the patient
Because theyre losing 15% to 20% of their body weightwithout intense diets or workouts
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 18 Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland Authors Hoffmann K, Michalak M , Paczkowska A Received 1 April 2025 Accepted for publication 1 July 2025 Published 7 August 2025 Volume 2025:18 Pages 27232738 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Halis Akturk Karolina Hoffmann, 1 Micha Michalak, 2 Anna Paczkowska 3 1 Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Pozna, Poland
It is intended to be used in combination with a reduced-calorie diet and increased physical activity
This is also why stacking supplements aggressively often backfires